Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microbubble-Enhanced Clotbust for Acute Ischemic Stroke
NCT00507806Phase 2Terminated
- Sponsor
- ImaRx Therapeutics, Inc.
- Start
- Mar 2005
01
Overview
Phase 2, open-label, single-arm trial of MRX-801 in ischemic stroke, sponsored by ImaRx Therapeutics, Inc. Primary endpoint: Symptomatic Intracranial Hemorrhage at 72 hours. Started Mar 2005; status: terminated.
02
Drugs
MRX-801
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00507806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00507806.